+

WO1994009767A1 - Nouvelle utilisation de compositions pharmaceutiques - Google Patents

Nouvelle utilisation de compositions pharmaceutiques Download PDF

Info

Publication number
WO1994009767A1
WO1994009767A1 PCT/EP1993/003001 EP9303001W WO9409767A1 WO 1994009767 A1 WO1994009767 A1 WO 1994009767A1 EP 9303001 W EP9303001 W EP 9303001W WO 9409767 A1 WO9409767 A1 WO 9409767A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
use according
composition
group
Prior art date
Application number
PCT/EP1993/003001
Other languages
English (en)
Inventor
Philip Lea
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of WO1994009767A1 publication Critical patent/WO1994009767A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin

Definitions

  • the present invention relates to the use of napthalene derivatives for the treatment of upper respiratory tract infections, in particular the treatment management or mitigation of cold, cold-like and/or flu symptoms, pharmaceutical compositions and methods of using such compositions.
  • naphthalene derivatives are known to possess useful anti-inflammatory activity and to be suitable for use in the treatment of various rheumatic and arthritic conditions. Such compounds are known as non-steroidal anti- inflammatory drugs (NSAID's).
  • NSAID's non-steroidal anti- inflammatory drugs
  • UK Patent No. 1474377 discloses pharmaceutical compositions which comprise a compound of formula (I):
  • X is a chlorine or bromine atom or a methoxyl, methylthio or alkyl group of 1-4 carbon atoms
  • X is methyloxy or methylthio
  • R j is hydrogen and A is a -CO group.
  • the compound of formula (I) in which X is methyloxy, Y is -CHR1-CH2- where R x is hydrogen and A is -CO (4-(6-methoxy- 2-naphthyl)butan-2-one) is commercially available for the treatment of rheumatic and arthritic conditions. It has the generic name nabumetone.
  • the compounds of formula (I) provide relief from symptoms associated with colds and flu and have utility as cold and/or flu treatments in mammals, including humans.
  • Compounds of formula (I) also have potential benefit for the treatment sinus pain and in allergy, for example, hayfever. Accordingly, the present invention provides for the use of a composition comprising a compound of formula (I) for the manufacture of a medicament for the treatment of symptoms associated with colds and/or flu.
  • X is suitably a methoxyl, methylthio or methyl group. Most suitably X is a methoxyl or methylthio group.
  • Particularly suitable compounds of the formula (I) include those of the formulae (II) and (III):
  • nabumetone (4-(6-methoxy-2-naphthyl)butan-2-one) of the formula (IV):
  • the compound nabumetone has been shown to confer both analgesic and anti ⁇ pyretic properties in mammals which renders it particularly beneficial for use in the treatment of symptoms associated with colds and flu which include both pain and elevated temperature.
  • Peripherally acting compounds i.e. those that act at the site of pain, such as salicylates (eg aspirin) paracetamol, propionic acids (eg ibuprofen, naproxen, fenoprofen, ketoprofen) and indol-pyrrol acetic acids (eg indomethacin) are known to provide effective pain relief. They are also recognised antipyretics. A number of these compounds are constituents of commercially available treatments for the relief of symptoms associated with colds and flu. Certain of these analgesic/antipyretic compounds, especially aspirin and paracetamol have a rapid onset of action, which is of benefit where rapid symtomatic relief is required. Paracetamol is also not a recognised gastric irritant and shows no significant gastrointestinal related irritation. The duration of action of certain of these peripherally acting drugs, eg aspirin and paracetamol, is however relatively short.
  • salicylates eg aspirin
  • propionic acids e
  • Suitable analgesic compounds for combination with a compound of formula (I) include ibuprofen, paracetamol and aspirin.
  • Paracetamol and aspirin are relatively quick acting but of short duration compared to ibuprofen; therefore a paracetamol or aspirin/nabumetone combination which would provide both fast-acting and long lasting relief in colds and/or flu is preferred.
  • compositions of this invention comprising a compound of formula (I) in combination with a peripherally acting analgesic compound.
  • the compositions of this invention may optionally include one or more other known therapeutic agents, particularly those commonly used in cough, cold and/or flu preparations, such as, for example a decongestant (e.g. nasal decongestant), an antitussive, an expectorant or an antihistamine. These would suitably be included in amounts ranging from 1-100 mg, preferably 5-50mg.
  • Suitable nasal decongestants include the sympathomimetic amines, eg. phenylpropanolamine, ephedrine, phenylephrine, pseudoephedrine and their pharmaceutically acceptable salts.
  • Suitable antitussives include dextromethorphan, pholcodine, codeine, noscapine and their pharmaceutically acceptable salts.
  • Suitable expectorants which include mucolytics are guaphenesin, ipecacuanha, ammonium salts, bromhexine hydrochloride and acetylcysteine.
  • Suitable antihistamines include ethanolamines (e.g diphenhydramine and doxylamine), ethylenediamines (e.g. mepyramine), alkylamines (eg chlorpheniramine), piperazines and phenothiazines (e.g. promethazine).
  • ethanolamines e.g diphenhydramine and doxylamine
  • ethylenediamines e.g. mepyramine
  • alkylamines eg chlorpheniramine
  • piperazines and phenothiazines e.g. promethazine
  • a further class of antihistamines are classed as the "non-sedating" type and would typically include astemizole, terfenadine and clemastine.
  • composition comprising a compound of formula(I) in combination with one or more of a peripherally acting analgesic compound, a decongestant, an antitussive, an expectorant or an antihistamine compound.
  • compositions of the present invention are suitably administered in oral dosage forms.
  • oral dosage forms include solid forms such as tablets, powders, effervescent powders, capsules eg soft and hard gelatin capsules with either solid or liquid fill, granules and lozenges.
  • liquid forms such as syrups and suspensions are also suitable for administration.
  • Solid oral dosage forms preferably contain from 5% to 95% (w/w) more preferably from 10% to 95% (w/w) and most preferably 25% to 95% (w/w) of the active components.
  • Liquid oral dosage forms preferably contain from 1% to 50% (w/w) more preferably 1% to 25% (w/w) and most preferably 3% to 10% (w/w) of the active components.
  • each dose could provide 0.1-lOg of a compound of formula (I). More typically 0.5- lg would be given as a single dose per day alone or in combination with other analgesics (typically 200-1000mg) and/or other suggested compounds used for the symptomatic relief of colds and flu.
  • the active components are incorporated into an orally acceptable pharmaceutical carrier using standard techniques used in the art of pharmaceutical formulations.
  • the active components are admixed with a pharmaceutically acceptable carrier.
  • compositions of the invention may be included in compositions of the invention.
  • Optional ingredients include, for example, natural or artificial sweeteners, flavouring agents, colourants and other such ingredients which may for example prolong and enhance shelf life.
  • the above active combinations can be formulated into a number of both solid and liquid oral dosage forms using standard excipients and formulation technology.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'un composé de la formule (I) pour la fabrication d'un médicament pour le traitement de symptômes associés avec le rhume et/ou la grippe. Dans cette formule, X est un atome de chlore ou de brome, ou un groupe méthoxyle, méthylthio ou alkyle ayant 1-4 atomes de carbone; Y est un groupe -CHR1-CH2- ou -CR1=CH- où R1 est un atome d'hydrogène ou un groupe méthyle et A est un groupe -CHOH ou -CO. On décrit en outre des compositions contenant un composé de la formule (I) en combinaison avec un composé analgésique à action périphérique et éventuellement un composé décongestionnant, antitussif, expectorant ou antihistaminique. Le composé préféré de la formule (I) est la nabumétone.
PCT/EP1993/003001 1992-10-31 1993-10-25 Nouvelle utilisation de compositions pharmaceutiques WO1994009767A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929222849A GB9222849D0 (en) 1992-10-31 1992-10-31 Novel use of pharmaceutical compositions
GB9222849.3 1992-10-31

Publications (1)

Publication Number Publication Date
WO1994009767A1 true WO1994009767A1 (fr) 1994-05-11

Family

ID=10724338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/003001 WO1994009767A1 (fr) 1992-10-31 1993-10-25 Nouvelle utilisation de compositions pharmaceutiques

Country Status (2)

Country Link
GB (1) GB9222849D0 (fr)
WO (1) WO1994009767A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004808A1 (fr) * 1995-07-28 1997-02-13 The Procter & Gamble Company Compositions contenant des analgesiques et des antihistaminiques et procedes de traitement d'affections respiratoires

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1474377A (en) * 1973-09-11 1977-05-25 Beecham Group Ltd Naphthalene derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1474377A (en) * 1973-09-11 1977-05-25 Beecham Group Ltd Naphthalene derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. ANDJELKOVIC ET AL.: "The influence of nabumetone and naproxen on the contraction of guinea-pig bronchial muscle.", EUR. J. PHARMACOL., vol. 183, no. 6, 1990, pages 2404 *
E.A. BOYLE ET AL: "Nabumetone(BRL 14777, 4-[6-methoxy-2-naphthyl]-butan-2-one) a new anti-inflammatory agent", J. PHARM. PHARMACOL., vol. 34, no. 9, 1982, pages 562 - 569 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004808A1 (fr) * 1995-07-28 1997-02-13 The Procter & Gamble Company Compositions contenant des analgesiques et des antihistaminiques et procedes de traitement d'affections respiratoires

Also Published As

Publication number Publication date
GB9222849D0 (en) 1992-12-16

Similar Documents

Publication Publication Date Title
US4749722A (en) Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US5025019A (en) Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4829064A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
EP0311677B1 (fr) Melanges contre la toux/le rhume comprenant des remedes d'antihistamine non sedative
US5196436A (en) Dextromethorphan antitussive compositions
JPH04501425A (ja) ロラタジン、イブプロフェンおよびプソイドエフェドリンを含む薬剤組成物
US4975426A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
JPH09502201A (ja) プロピオン酸非ステロイド系抗炎症剤のアミノ酸塩とうっ血除去剤、去痰剤、抗ヒスタミン剤及び鎮咳剤のうち少くとも１種を含有した組成物
ES2397262T3 (es) Composiciones líquidas de absorción rápida que contienen una amina y un AINE
JPS60208913A (ja) 高めた無痛覚を与える製薬製品
CA2455939A1 (fr) Preparation de sucralose permettant de masquer des gouts desagreables
JPH08502288A (ja) 感昌症状を治療するための医薬組成物及び用法
JPH01268633A (ja) Ｌ−ドーパの直腸被吸収性形態
EP1014983A1 (fr) Compositions et procedes de traitement de troubles respiratoires
JP5542309B2 (ja) 経口医薬組成物
JPH08506808A (ja) 呼吸障害治療用組成物の製造における鎮痛剤ｓ（＋）対掌体の利用
JPH11510168A (ja) 呼吸障害を処理するための鎮痛剤及び抗ヒスタミン剤を含有する組成物及び方法
US4840962A (en) Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
WO1994009767A1 (fr) Nouvelle utilisation de compositions pharmaceutiques
CA2129676C (fr) Compositions antitussive de dextromethorphane
IE913184A1 (en) Method for treating respiratory disorders
CA2076149A1 (fr) Potentialisation de l'effet antitussif de la dextromethorphane
JP2006001920A (ja) 医薬製剤
JP2004331660A5 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载